Strensiq (asfotase alfa) / AstraZeneca 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Strensiq (asfotase alfa) / AstraZeneca
RESTORE, NCT06015750: Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia

Not yet recruiting
4
8
Europe, US
methotrexate, rituximab, bortezomib, IVIg, Folic Acid
Alexion Pharmaceuticals, Inc.
Hypophosphatasia
09/28
09/28
CHESTNUT, NCT06079372: Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa

Recruiting
3
40
Europe, Canada, Japan, US, RoW
ALXN1850, asfotase alfa
Alexion Pharmaceuticals, Inc.
Hypophosphatasia
06/25
01/28
MULBERRY, NCT06079359: Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP

Recruiting
3
30
Europe, Canada, US, RoW
ALXN1850, Placebo
Alexion Pharmaceuticals, Inc.
Hypophosphatasia
09/25
04/28
HICKORY, NCT06079281: Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa

Recruiting
3
114
Europe, Canada, Japan, US, RoW
ALXN1850, Placebo
Alexion Pharmaceuticals, Inc.
Hypophosphatasia
12/25
07/28
ALXN1850-HPP-301, ChiCTR2400082318:

Not yet recruiting
3
114
 
ALXN1850; placebo
Peking Union Medical College Hospital; Peking Union Medical College Hospital, AZ
adolescent (≥ 12 to < 18 years of age at Day 1) and adult (≥ 18 years of age at Day 1) participants with HPP who have not previously been treated with asfotase alfa.
 
 
NCT04195763: Patient Reported Outcomes in Adults With Pediatric-onset Hypophosphatasia Treated With Strensiq® (Asfotase Alfa)

Completed
N/A
50
US
asfotase alfa, Strensiq®
Alexion Pharmaceuticals, Inc., Xcenda, LLC
Hypophosphatasia
04/24
04/24
NCT02306720: Registry of Patients With Hypophosphatasia

Enrolling by invitation
N/A
900
Europe, Canada, US, RoW
Alexion Pharmaceuticals, Inc.
Hypophosphatasia (HPP)
12/31
12/31
NCT05234567: A Prospective Sub-Study of the Global Hypophosphatasia Registry

Recruiting
N/A
30
US
Asfotase Alfa, Strensiq
Alexion Pharmaceuticals, Inc.
Hypophosphatasia
08/29
08/29

Download Options